Prothena (PRTA) News Today $14.92 -0.89 (-5.63%) As of 12:40 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Zacks Research Issues Positive Outlook for Prothena EarningsProthena Co. plc (NASDAQ:PRTA - Free Report) - Equities research analysts at Zacks Research raised their Q2 2025 earnings estimates for shares of Prothena in a research note issued on Monday, January 27th. Zacks Research analyst E. Bagri now forecasts that the biotechnology company will post earnJanuary 30 at 7:53 AM | marketbeat.comDuncan Williams Asset Management LLC Purchases 20,450 Shares of Prothena Co. plc (NASDAQ:PRTA)Duncan Williams Asset Management LLC lifted its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 41.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 69,199 shares of the biotechnologJanuary 26, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from AnalystsShares of Prothena Co. plc (NASDAQ:PRTA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have givJanuary 26, 2025 | marketbeat.comCantor Fitzgerald Estimates Prothena FY2025 EarningsJanuary 24, 2025 | americanbankingnews.comProthena (NASDAQ:PRTA) Trading 6.7% Higher - Here's WhyProthena (NASDAQ:PRTA) Shares Up 6.7% - Still a Buy?January 23, 2025 | marketbeat.comCantor Fitzgerald Comments on Prothena FY2025 EarningsProthena Co. plc (NASDAQ:PRTA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Prothena in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan anticipates that the biotechnology company will post earniJanuary 22, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Buys Shares of 52,284 Prothena Co. plc (NASDAQ:PRTA)Hennion & Walsh Asset Management Inc. purchased a new position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 52,284 sharesJanuary 20, 2025 | marketbeat.comJPMorgan Chase & Co. Has $3.35 Million Stock Position in Prothena Co. plc (NASDAQ:PRTA)JPMorgan Chase & Co. lessened its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 32.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 199,986 shares of the biotechnology company's stock after selling 95,979 sJanuary 20, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Shares Up 6.8% - Time to Buy?Prothena (NASDAQ:PRTA) Trading 6.8% Higher - Time to Buy?January 17, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Purchased by Barclays PLCBarclays PLC raised its holdings in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 110.2% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 95,222 shares of the biotechnology company's stock after purchasing an additional 49,916 sharJanuary 12, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Trading Down 9% - What's Next?Prothena (NASDAQ:PRTA) Trading Down 9% - Here's What HappenedJanuary 10, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Trading Up 6.5% - What's Next?Prothena (NASDAQ:PRTA) Shares Up 6.5% - Here's WhyJanuary 7, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesProthena Co. plc (NASDAQ:PRTA - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have given a buyJanuary 1, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 2.6% - Should You Sell?Prothena (NASDAQ:PRTA) Stock Price Down 2.6% - Should You Sell?December 31, 2024 | marketbeat.comProthena Announces Board of Directors UpdateDecember 30, 2024 | businesswire.comProthena Co. plc (NASDAQ:PRTA) Shares Bought by Barclays PLCBarclays PLC grew its position in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 110.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,222 shares of the biotechnology company's stoDecember 28, 2024 | marketbeat.comWe're Not Very Worried About Prothena's (NASDAQ:PRTA) Cash Burn RateDecember 25, 2024 | finance.yahoo.comProthena Co. plc (NASDAQ:PRTA) Position Trimmed by State Street CorpState Street Corp lessened its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 13.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,674,909 shares of the biotechnology company's stock aftDecember 23, 2024 | marketbeat.comProthena Surges After Parkinson's Drug Misses Primary EndpointDecember 22, 2024 | seekingalpha.comOptimistic Outlook on Prothena Despite Phase 2b PADOVA SetbacksDecember 21, 2024 | markets.businessinsider.comChardan Capital Initiates Coverage of Prothena (PRTA) with Buy RecommendationDecember 20, 2024 | msn.comProthena price target lowered to $48 from $84 at H.C. WainwrightDecember 20, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Prothena (NASDAQ:PRTA)HC Wainwright reissued a "buy" rating and issued a $48.00 price target (down previously from $84.00) on shares of Prothena in a research note on Friday.December 20, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Now Covered by Chardan CapitalChardan Capital initiated coverage on Prothena in a research note on Friday. They set a "buy" rating and a $40.00 price objective for the company.December 20, 2024 | marketbeat.comProthena stock soars despite study missDecember 20, 2024 | uk.investing.comBank of America Lowers Prothena (NASDAQ:PRTA) Price Target to $22.00Bank of America lowered their price objective on shares of Prothena from $26.00 to $22.00 and set a "neutral" rating on the stock in a research report on Thursday.December 19, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Hits New 52-Week Low - Here's WhyProthena (NASDAQ:PRTA) Sets New 12-Month Low - Time to Sell?December 19, 2024 | marketbeat.comRoche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's DiseaseDecember 19, 2024 | businesswire.comProthena (NASDAQ:PRTA) Stock Price Down 3.6% - Time to Sell?Prothena (NASDAQ:PRTA) Stock Price Down 3.6% - Should You Sell?December 18, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Up 7.8% - What's Next?Prothena (NASDAQ:PRTA) Trading 7.8% Higher - Time to Buy?December 17, 2024 | marketbeat.comProthena (PRTA) Receives a Buy from OppenheimerDecember 17, 2024 | markets.businessinsider.comJanus Henderson Group PLC Has $301,000 Holdings in Prothena Co. plc (NASDAQ:PRTA)Janus Henderson Group PLC lessened its position in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 98.2% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 18,047 shares of the biotechnology company's stock after selling 1,008,511 shares duDecember 16, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Hits New 52-Week Low - Should You Sell?Prothena (NASDAQ:PRTA) Reaches New 52-Week Low - Time to Sell?December 13, 2024 | marketbeat.comWellington Management Group LLP Purchases 539,359 Shares of Prothena Co. plc (NASDAQ:PRTA)Wellington Management Group LLP increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 14.8% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,178,788 shares of the biotechnologDecember 11, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Prothena Co. plc (NASDAQ:PRTA - Free Report) by 1,122.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 526,748 shares of the biotechnology company's stock after purchasingDecember 9, 2024 | marketbeat.comSystematic Financial Management LP Has $136,000 Stock Position in Prothena Co. plc (NASDAQ:PRTA)Systematic Financial Management LP lessened its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 95.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,125 shares of the biotechnology company's stock afterDecember 7, 2024 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Average Recommendation of "Moderate Buy" by AnalystsProthena Co. plc (NASDAQ:PRTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are currently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the companyDecember 7, 2024 | marketbeat.comFY2024 EPS Estimates for Prothena Lifted by Zacks ResearchProthena Co. plc (NASDAQ:PRTA - Free Report) - Research analysts at Zacks Research increased their FY2024 EPS estimates for shares of Prothena in a report issued on Tuesday, December 3rd. Zacks Research analyst E. Bagri now expects that the biotechnology company will post earnings per share of ($December 6, 2024 | marketbeat.comProthena FY2024 EPS Forecast Raised by Cantor FitzgeraldProthena Co. plc (NASDAQ:PRTA - Free Report) - Analysts at Cantor Fitzgerald boosted their FY2024 earnings per share estimates for shares of Prothena in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biotechnology companNovember 18, 2024 | marketbeat.comFY2024 EPS Estimates for Prothena Cut by HC WainwrightProthena Co. plc (NASDAQ:PRTA - Free Report) - Equities research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Prothena in a research note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the biotechnology companyNovember 18, 2024 | marketbeat.comProthena's SWOT analysis: stock poised for potential breakthroughs amid risksNovember 15, 2024 | investing.comProthena (NASDAQ:PRTA) Hits New 12-Month Low - What's Next?Prothena (NASDAQ:PRTA) Hits New 12-Month Low - Time to Sell?November 15, 2024 | marketbeat.comHC Wainwright Increases Earnings Estimates for ProthenaProthena Co. plc (NASDAQ:PRTA - Free Report) - Investment analysts at HC Wainwright lifted their FY2028 earnings per share estimates for shares of Prothena in a research report issued on Wednesday, November 13th. HC Wainwright analyst A. Fein now forecasts that the biotechnology company will postNovember 15, 2024 | marketbeat.comProthena’s Strategic Advancements and Financial Strength Underpin Buy RatingNovember 14, 2024 | markets.businessinsider.comProthena’s Promising Therapeutic Developments and Positive Trial Outcomes Justify Buy RatingNovember 14, 2024 | markets.businessinsider.comProthena (NASDAQ:PRTA) Given "Buy" Rating at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $84.00 price target on shares of Prothena in a report on Wednesday.November 13, 2024 | marketbeat.comProthena (NASDAQ:PRTA) Issues Quarterly Earnings Results, Beats Estimates By $0.08 EPSProthena (NASDAQ:PRTA - Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.18) by $0.08. The business had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The firm's revenue was down 98.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.38 EPS.November 13, 2024 | marketbeat.comProthena Reports Third Quarter 2024 Financial Results and Business HighlightsNovember 13, 2024 | finanznachrichten.deProthena Corporation Reports Q3 2024 Financial ResultsNovember 13, 2024 | markets.businessinsider.comProthena Co. plc (NASDAQ:PRTA) Receives Average Rating of "Moderate Buy" from BrokeragesProthena Co. plc (NASDAQ:PRTA - Get Free Report) has been given a consensus rating of "Moderate Buy" by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating toNovember 12, 2024 | marketbeat.com Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTA Media Mentions By Week PRTA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PRTA News Sentiment▼1.150.76▲Average Medical News Sentiment PRTA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PRTA Articles This Week▼83▲PRTA Articles Average Week Get Prothena News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Arcellx News Today Denali Therapeutics News Today Immunovant News Today Twist Bioscience News Today Xenon Pharmaceuticals News Today ACADIA Pharmaceuticals News Today Vericel News Today Zai Lab News Today MoonLake Immunotherapeutics News Today MorphoSys News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PRTA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
